Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHA5ME)

• Drug Name: AZD-9684 Drug Info
• Synonyms: Laudanosine; DL-Laudanosine; 1699-51-0; (+-)-Laudanosine; Laudanosine (R,S); (R,S)-Laudanosine; EINECS 216-923-9; NSC 94267; AI3-61890; 20412-65-1; NSC35045; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline; (+-)-1,2,3,4-Tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinoline; 1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline; ISOQUINOLINE, 1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-1-VERATRYL-, (+-)-

Indication

Disease Entry	ICD 11	Status	REF
Thrombosis	DB61-GB90	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 87609775
  TTD Drug ID: DMHA5ME

Molecule-Related Drug Atlas

Drug(s) Targeting Neuronal acetylcholine receptor alpha-7 (CHRNA7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ziprasidone	DMM58JY	Bipolar disorder	6A60	Approved	[4]
ALCURONIUM	DM2U4XQ	Anaesthesia	9A78.6	Approved	[5]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[6]
CYTISINE	DMUF0BJ	Tobacco dependence	6C4A.2	Phase 3	[7]
EVP-6124	DMLQO7F	Alzheimer disease	8A20	Phase 3	[8]
GTS-21	DMEN5KA	Parkinson disease	8A00.0	Phase 2	[9]
JNJ-39393406	DMUOEKM	Depression	6A70-6A7Z	Phase 2	[10]
ABT-126	DM2OS51	Alzheimer disease	8A20	Phase 2	[11]
TC-6987	DMNFP21	Asthma	CA23	Phase 2	[12]
AQW-051	DMD2RFO	Alzheimer disease	8A20	Phase 2	[13]

Drug(s) Targeting Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SIB-1533A	DMR5FD9	Discovery agent	N.A.	Investigative	[14]
18-Methoxycoronaridine	DMTJ384	Drug abuse	6C4G.1Z	Investigative	[15]
Ibogaine	DM3HJX7	Discovery agent	N.A.	Investigative	[15]

Drug(s) Targeting Neuronal acetylcholine receptor beta-2 (CHRNB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CYTISINE	DMUF0BJ	Tobacco dependence	6C4A.2	Phase 3	[16]
TC-5214	DM8AM60	Palmar hyperhidrosis	EE00.00	Phase 2	[17]
SUVN-911	DMLPBVF	Major depressive disorder	6A70.3	Phase 1	[18]
ABT-594	DMGMBCW	N. A.	N. A.	Discontinued in Phase 2	[19]
ABT-418	DMNP72I	Alzheimer disease	8A20	Discontinued in Phase 2	[14]
HOMOEPIBATIDINE	DMHP9WV	N. A.	N. A.	Terminated	[16]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[20]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	DMDUGZS	Discovery agent	N.A.	Investigative	[21]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	DMDUI8R	Discovery agent	N.A.	Investigative	[21]
BOLDINE	DMMVB5P	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting Carboxypeptidase B2 (CPB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR-126119	DMKHM7O	Cerebrovascular ischaemia	8B1Z	Phase 1	[23]
UK-396082	DMFYKDX	Thrombosis	DB61-GB90	Phase 1	[24]
DS-1040	DMXCN37	Ischemic stroke	8B11.5Z	Phase 1	[25]
SAR-104772	DMQ9ZY0	Cerebrovascular ischaemia	8B1Z	Phase 1	[26]
PMID14640538C3	DMR2L6X	Discovery agent	N.A.	Investigative	[27]
DL-benzylsuccinic acid	DMHI9ZJ	Discovery agent	N.A.	Investigative	[28]
PMID19954973C4	DMDYZE5	Discovery agent	N.A.	Investigative	[24]
3-mercapto-2-(piperidin-3-yl)propanoic acid	DMPJBNC	Discovery agent	N.A.	Investigative	[29]
6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid	DMMUE05	Discovery agent	N.A.	Investigative	[30]
3-mercapto-2-(piperidin-4-yl)propanoic acid	DMYQG7A	Discovery agent	N.A.	Investigative	[29]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carboxypeptidase B2 (CPB2)	TTP18AY	CBPB2_HUMAN	Inhibitor	[2]
Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3)	TTMT0HG	ACHA2_HUMAN; ACHA3_HUMAN	Antagonist	[3]
Neuronal acetylcholine receptor alpha-7 (CHRNA7)	TTLA931	ACHA7_HUMAN	Antagonist	[3]
Neuronal acetylcholine receptor beta-2 (CHRNB2)	TT5KPZR	ACHB2_HUMAN	Antagonist	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018349)
• [2] Clinical pipeline report, company report or official report of AstraZeneca.
• [3] Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology. 2001 Apr;94(4):643-51.
• [4] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [5] Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
• [6] Clinical pipeline report, company report or official report of Roche (2009).
• [7] 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.
• [8] Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.
• [9] The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81.
• [10] Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204.
• [11] A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.
• [12] ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
• [13] AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.
• [14] Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000 Mar-Apr;31(2):131-44.
• [15] Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol. 2002 Mar 1;438(1-2):99-105.
• [16] Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport. 1999 Dec 16;10(18):3909-13.
• [20] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [21] Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
• [22] Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72.
• [23] TAFIa inhibitors in the treatment of thrombosis. Curr Opin Drug Discov Devel. 2008 Jul;11(4):480-6.
• [24] Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6.
• [25] Clinical pipeline report, company report or official report of Daiichi Sankyo.
• [26] Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy . Journal of Thrombosis and Haemostasis Volume 7, Issue 12, pages 1962-1971, December 2009.
• [27] Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7.
• [28] A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71.
• [29] 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54.
• [30] Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group. Bioorg Med Chem Lett. 2004 May 3;14(9):2141-5.